Ratings BIO-UV Group

Equities

ALTUV

FR0013345493

Market Closed - Euronext Paris 11:18:58 2024-06-17 am EDT 5-day change 1st Jan Change
1.944 EUR -4.47% Intraday chart for BIO-UV Group -13.02% -20.49%

Summary

  • Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

Strengths

  • The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.53 for the 2024 fiscal year.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
  • For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • Over the past four months, analysts' average price target has been revised upwards significantly.

Weaknesses

  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • The company sustains low margins.
  • The group shows a rather high level of debt in proportion to its EBITDA.
  • The overall consensus opinion of analysts has deteriorated sharply over the past four months.
  • Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Sector: Electrical Components & Equipment

1st Jan change Capi. Investor Rating ESG Refinitiv
-20.49% 21.11M -
-1.07% 141B
A
+22.73% 134B
B+
+35.09% 130B
B+
+10.32% 61.42B
A-
+2.20% 39.01B
B
+86.45% 33.52B
C
+5.04% 29.99B
B
-16.74% 29.47B
B
+12.28% 28.23B
B+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
-
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes